| Name | Abcam |
|---|---|
| Epic | ABC |
| Isin | GB00B6774699 |
| Index | AIM50 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,226.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2,810.87 | Debt ratio | n/a |
| Shares in issue | 229.00 | Debt-to-equity ratio | n/a |
| P/E ratio | 26.3 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | 14.74 |
| Dividend cover | n/a | EPS growth | 381 |
| Earning per share | 15.27 | 52-week high / low | 1,049.00p / 1,750.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Interim | 2020-03-19 | 2020-04-17 | 3.55p |
| Final | 2019-11-07 | 2019-11-29 | 8.58p |
| Interim | 2019-03-14 | 2019-04-12 | 3.55p |
| Final | 2018-11-08 | 2018-11-30 | 8.58p |
| Interim | 2018-03-15 | 2018-04-12 | 3.42p |
| Company name | Abcam |
|---|---|
| Address | Discovery Drive, Cambridge Biomedical Campus, Cambridge, United Kingdom , CB2 0AX |
| Telephone | +44 (0)1223 696 000 |
| Website | http://www.abcam.com |
| Director | Position |
|---|---|
| Mr Alan Thomas Hirzel | CEO |
| Mr Michael Baldock | CFO |
| Ms Luba Greenwood | Non-Executive Director |
| Mr Peter Allen | Non-Executive Chairman |
| Mr Giles Kerr | Senior Independent Director |
| Mr Bessie Lee | Independent Non-Executive Director |
| Ms Mara G Aspinall | Independent Non-Executive Director |
| Mr Mark Capone | Independent Non-Executive Director |
| Ms Sally W. Crawford | Independent Non-Executive Director |
| Assets £ (m) | 2021 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/21 | 30/06/21 | 30/06/20 |
| Intangible asssets and goodwill | 599 | 336.2 | 347.2 |
| Investments and other non-current assets | 3.5 | 3.5 | 7 |
| Total non-current assets | 774.6 | 504.8 | 532.6 |
| Inventory / work in progress | 58.2 | 45.9 | 40.7 |
| Trade and other receivables | 57.7 | 46.4 | 44.4 |
| Cash and equivalents | 95.1 | 219.9 | 187.3 |
| Other current assets and asset held for resale | 0.5 | 7.5 | 6.4 |
| Total of all assets | 986.1 | 824.5 | 811.4 |
| Liabilities £ (m) | 2021 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 187.2 | 66.9 | 159.6 |
| Long term liabilities | 142.8 | 122.9 | 149.2 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 330 | 189.8 | 308.8 |
| Net assets £ (m) | 2021 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 656.1 | 634.7 | 502.6 |
| Equity £ (m) | 2021 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 0.5 | 0.5 | 0.4 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 289.6 | 282.2 | 255.7 |
| Share premium account | 268.3 | 265.5 | 138.2 |
| Total equity | 656.1 | 634.7 | 502.6 |
| Income £ (m) | 2021 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 24.4 | 28.2 | 10.5 |
| Pre-tax profit | 20.3 | 25.4 | 8.4 |